由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
Stock版 - 医药龙头股PFE有疫苗消息 Pre-market 36.86 +1.24 (3.48%)
相关主题
EROC questions, please helpLLEN暂停了
MIPSSCTY明天ER?
WNR 生不逢时ARGS快了
谁还在关注WNR?(陆灿蜜月度完了没?)美股 CLDN 和 港股 08021 是咋回事?
Plug 飞了Costco June sales number
Dang 要飞了昨天进了很多MDVN
icahn 公司昨天就提醒你们要关注icahn 的退特了PFE 为什么跌这么厉害?
afop要搞增发还值得入吗靠,PFE放量狂跌,135M的量
相关话题的讨论汇总
话题: biontech话题: clinical话题: pfizer话题: covid话题: trial
1 (共1页)
V***6
发帖数: 333
1
BioNTech and Pfizer announce regulatory approval from German authority Paul-
Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine
candidates
GlobeNewswire•April 22, 2020
- First COVID-19-related clinical trial to start in Germany
- Initial dose escalation phase to target dose range of 1μg to 100μg
- Clinical supply from BioNTech’s GMP-certified mRNA production facilities
in Europe
- Four vaccine candidates to enter clinical development
MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE
(Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (PFE), have
announced today that the German regulatory authority, the Paul-Ehrlich-
Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162
vaccine program to prevent COVID-19 infection. BioNTech and Pfizer are
jointly developing BNT162. The trial is the first clinical trial of a COVID-
19 vaccine candidate to start in Germany, and is part of a global
development program. Pfizer and BioNTech will also conduct trials for BNT162
in the United States upon regulatory approval, which is expected shortly.
1 (共1页)
相关主题
新人弱问PFEPlug 飞了
Bad deal for PFE?Dang 要飞了
AGN真要变VRX了。。。icahn 公司昨天就提醒你们要关注icahn 的退特了
Institute Ownafop要搞增发还值得入吗
EROC questions, please helpLLEN暂停了
MIPSSCTY明天ER?
WNR 生不逢时ARGS快了
谁还在关注WNR?(陆灿蜜月度完了没?)美股 CLDN 和 港股 08021 是咋回事?
相关话题的讨论汇总
话题: biontech话题: clinical话题: pfizer话题: covid话题: trial